Antibody-Drug Conjugates (ADC) (Trastuzumab Emtansine and Trastuzumab Deruxtecan)

Interstitial lung diseases were found in 7 of 490 cases (1.4%) in an international phase III study in subjects with inoperable or recurrent breast cancer and in 1 of 73 cases (1.4%) in a phase II study in Japan [1] (Fig. 9.1). An analysis (KATHERINE study) on the use of trastuzumab emtansine in postoperative adjuvant chemotherapy showed 21 cases (2.8%) of interstitial lung disease in 740 subjects, and the 11 cases were radiation pneumonitis [2] (Fig. 9.2). In addition, it was reported that all 21 cases received radiation therapy. Compared to other ADCs, the frequency of drug-induced lung injuries was lower.